Wipro Consumer Care & Lighting has signed definitive agreements to acquire the Good Home and Eva brands from TTK Healthcare for ₹256 crore, marking its 17th acquisition to date. This strategic move significantly strengthens Wipro's presence in home care and personal care segments by filling critical product category gaps. Good Home operates in air care, odour removers, scrubbers, and drain cleaners, while Eva offers deodorant body sprays, no-gas perfumes, underarm roll-ons, and talcum powders.
The acquisition addresses specific strategic gaps in Wipro's existing portfolio. In home care, Good Home provides immediate entry into the growing air care category and specialized cleaning products—segments where Wipro had limited presence. The air care market in India is expected to grow at 9.3% CAGR through 2030, driven by increasing indoor hygiene awareness and wellness-centric aromatherapy trends. In personal care, Eva strengthens Wipro's deodorant and fragrance portfolio, particularly in no-gas formats and roll-ons that cater to evolving consumer preferences. The Indian deodorant market is projected to grow at approximately 12% CAGR over the next five years.
This acquisition aligns perfectly with Wipro Consumer Care's stated strategy of building a diversified FMCG business through a mix of organic growth and acquisitions.
The combined revenues of Good Home and Eva brands, totaling ₹148 crore in FY26, would contribute approximately 1.37% to Wipro Consumer Care & Lighting's FY26 revenues of ₹10,800 crore.
The discount likely reflects the mixed performance of the two brands—Good Home demonstrated 9% revenue growth in FY26, while Eva reported negative growth of around 4%. Others
Several factors justify this valuation. First, the acquisition provides immediate entry into high-growth categories without the time and investment required for organic brand building. Second, both brands have established consumer trust and distinct market positions. Third, there's significant turnaround potential, particularly for Eva, under Wipro's management capabilities. Fourth, the brands have gained acceptance in modern trade and e-commerce channels, providing immediate market access.
Wipro Consumer Care plans to achieve synergies and cost efficiencies through multiple avenues. Manufacturing scale benefits from consolidated procurement could yield 8-12% cost savings on raw materials. Integration into Wipro's existing distribution network across 20 countries will reduce logistics costs. Shared corporate services and marketing infrastructure are expected to reduce administrative and marketing costs by 15-20%. Overall margin improvements of 8-12 percentage points are targeted over 2-3 years post-acquisition.
The expected payback period ranges from 5.5-6 years under base case assumptions, with ROI of 18-22% IRR. Under optimistic scenarios with faster revenue growth (15% CAGR) and quicker margin improvement, the payback period could shorten to 4-4.5 years. These projections assume revenue growth of 12% CAGR and margin expansion from current estimated levels of 15% to target levels of 22%.
The acquisition comes at a challenging time for Wipro Enterprises, which reported Q1 FY27 net profit of ₹3,357 crore, representing only 0.75% year-on-year growth despite revenue growth of 10% to ₹24,479 crore. Operating margins fell to 16.0%, declining 120 basis points year-on-year and 130 basis points quarter-on-quarter, reflecting cost pressures from wage inflation and AI investments.
However, the ₹256 crore acquisition represents only about 0.8% of Wipro Enterprises' Q1 revenue, making it a manageable commitment relative to overall financial scale. The company's strong cash flow generation and low debt levels (Debt/Equity ratio of 0.0978) provide significant headroom for strategic investments. Despite the muted outlook, this acquisition aligns with a disciplined capital allocation strategy focused on margin-accretive, cash-generating assets that provide diversification from IT services cyclicality.
Wipro Consumer Care plans to leverage its extensive distribution infrastructure to expand Good Home and Eva brands. The company has presence in 20 countries with 16 manufacturing units across India, Malaysia, Indonesia, Philippines, Vietnam, China, and South Africa. More than 50% of its revenue comes from international markets. In India, Wipro has strong rural presence with consistent expansion efforts, and quick commerce integration showing 3-4x growth in this channel.
For international expansion, Kumar Chander, CEO of Wipro Consumer Care & Lighting, stated: "Air care is becoming an exciting category not just in India but across Southeast Asia, South Africa and China. We may take the products to these markets, even if not under the same brand name. The brands may remain local, but the backend can be common. That gives us procurement scale and allows us to invest more behind the brands".
Product innovation will be supported by Wipro's state-of-the-art Research and Innovation Centers in India, Malaysia, China, Philippines, and South Africa. The company specializes in personal care technology, pharmaceutical cosmetics, and home care products, with a focus on natural ingredients and sustainable development. Recent investments include a Food Research and Innovation Centre in Bengaluru opened in August 2023.
Manufacturing integration will focus on production consolidation, supply chain integration, and technology implementation. Wipro plans to utilize existing manufacturing capacity for Good Home and Eva products, implement lean manufacturing principles, and invest in automation for improved efficiency and quality.
Wipro Consumer Care – Ventures and the M&A team, led by Sumit Keshan, will play a central role in post-acquisition integration. The Ventures division, which focuses on personal care, home care, wellness, food, and pet care sectors in India and South East Asia, will provide strategic oversight, operational integration support, and growth strategy guidance.
The acquisition significantly strengthens Wipro Consumer Care's competitive position against established FMCG players. In the home care market, Hindustan Unilever leads with 31.7% value share, followed by Rohit Surfactants (9.9%) and Reckitt Benckiser (8.5%). In deodorants, Fogg leads with 15.8% market share, followed by Hindustan Unilever (31.5% with Axe brand), Nivea, Engage, Park Avenue, and Wild Stone.
Sustained consumer demand in home care, air care, and fragrance categories provides strong tailwinds for market share growth. The India Home Care market is driven by rising disposable incomes, increasing urbanization, and growing hygiene awareness. The air care market is expected to grow at 9.3% CAGR, while deodorants are projected to grow at approximately 12% CAGR.
The acquisition will intensify competition in both deodorant and air care markets, potentially accelerating innovation, marketing spend, and format development across the industry. It may also trigger competitive responses from major players like HUL, Godrej, and Dabur in terms of increased marketing investment, product innovation acceleration, and strategic pricing responses.
For TTK Healthcare, the divestment represents strategic portfolio optimization aligned with focus on core healthcare businesses. The company has been on a path of portfolio rationalization since 2022, moving away from capital-intensive human pharmaceuticals to focus on high-margin medical devices and consumer segments. TTK previously sold its human pharma business for ₹805 crore in 2022.
The divestment will impact TTK's revenue profile by reducing topline by approximately 17% (~₹148 crore) starting next fiscal year. However, it allows the company to focus on core healthcare segments including Medical Devices (Heart Valve Division ₹29.81 crore, Ortho Division ₹77 crore with 27% growth), Animal Welfare (double-digit growth), Foods (₹150.36 crore with 14% growth), and Protective Devices. Others +3
This statement reveals TTK's honest assessment of its own FMCG capability limitations in distribution scale, marketing investment, manufacturing scale, and financial resources compared to larger conglomerates like Wipro.
The ₹256 crore proceeds (plus GST) will significantly boost TTK's already comfortable cash reserves of ₹927 crore (as of June 2025), with post-deal cash reserves expected to exceed ₹1,100 crore. The company plans to utilize these proceeds to strengthen healthcare business operations, including Medical Devices expansion, Animal Welfare growth, Protective Devices recovery, and potential strategic acquisitions in healthcare segments.
